TCR2 Therapeutics Inc. Profile Avatar - Palmy Investing

TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (T…

Biotechnology
US, Cambridge [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

TCR2 Therapeutics Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of TCRR's Analysis
CIK: 1750019 CUSIP: 87808K106 ISIN: US87808K1060 LEI: - UEI: -
Secondary Listings
TCRR has no secondary listings inside our databases.